| Feature | Ipamorelin (Ipa) | CJC-1295 (often with Ipamorelin) | Tesamorelin (Tesa) | Human Growth Hormone (HGH) | Anavar (Oxandrolone) | Testosterone Cypionate (Test-C) |
| Type of Substance | Growth Hormone Secretagogue Peptide | GHRH Analog Peptide (longer acting) | GHRH Analog Peptide (highly targeted) | Recombinant Human Growth Hormone (exogenous) | Oral Anabolic Androgenic Steroid (AAS) | Injectable Anabolic Androgenic Steroid (AAS) |
| Mechanism of Action for Fat Loss | Stimulates natural GH release in pulsatile manner, leading to increased lipolysis and metabolism. | Stimulates sustained natural GH release, leading to increased lipolysis and metabolism. | Stimulates natural GH release, uniquely targeting and reducing visceral adipose tissue (VAT). | Direct lipolytic effects; increases metabolism; in deficient individuals, restores fat metabolism. | Directly promotes lipolysis; preserves/builds lean muscle mass, increasing metabolic rate. | Promotes lean muscle mass, increasing metabolic rate; may directly influence fat cell metabolism; plays a role in overall body composition. |
| Primary Fat Target | General fat loss (subcutaneous and visceral) | General fat loss (subcutaneous and visceral) | Specifically Visceral Adipose Tissue (VAT) | General fat loss (subcutaneous and visceral), especially in deficient states. | General fat loss (subcutaneous and visceral), with notable effects on abdominal fat. | General fat loss (subcutaneous and visceral), particularly in individuals with low testosterone. |
| Fat Burning Efficacy (General) | Moderate (as part of overall body recomposition) | Moderate to Good (as part of overall body recomposition) | High for VAT; less pronounced for overall subcutaneous fat. | Moderate to High in GH-deficient individuals; Modest in healthy individuals. | High (especially for preserving muscle during caloric deficit). | Moderate to High (especially in hypogonadal men, contributes to better body composition). |
| Targeted Fat Reduction | Indirect via GH increase | Indirect via sustained GH increase | Highly targeted to VAT | General, but can reduce VAT in deficient states. | General, with strong effects on body recomposition. | General, helps optimize body composition. |
| Muscle Preservation/Gain | Yes, by increasing GH and IGF-1 | Yes, by increasing GH and IGF-1 | Yes, due to increased GH and IGF-1 | Yes, promotes muscle growth and preservation, especially in deficient states. | Significant, known for preserving lean mass during cutting. | Significant, primary role is muscle growth and strength. |
| Typical Use Context | Anti-aging, general wellness, body recomposition | Anti-aging, general wellness, body recomposition, recovery | HIV-associated lipodystrophy (FDA-approved), some off-label for VAT. | GH deficiency treatment; some off-label in sports (controversial). | Medical: muscle wasting conditions; Illicit: bodybuilding (cutting). | Medical: Testosterone Replacement Therapy (TRT) for hypogonadism; Illicit: bodybuilding. |
| Legal Status (USA) | Prescription peptide (generally) | Prescription peptide (generally) | Prescription drug (FDA-approved) | Prescription drug (Controlled substance for non-medical use) | Prescription drug (Controlled substance) | Prescription drug (Controlled substance) |
| Potential Side Effects | Mild (e.g., injection site reactions, transient flushing) | Mild (e.g., injection site reactions, transient flushing) | Mild (e.g., injection site reactions, headache, joint pain) | Swelling, joint pain, carpal tunnel, insulin resistance, acromegaly (with abuse). | Liver toxicity, cholesterol changes, virilization in females, hair loss, acne. | Estrogen-related (gynecomastia, water retention), acne, hair loss, prostate issues, cardiovascular risks. |